ETON Eton Pharmaceuticals

• None no insider bought on the open market
• $25.4M sold by 5 insiders outside a trading plan
• None no planned (10b5-1) sales

1. Insider
   Trade
   Value
   Traded, filed
2. David Krempa Chief Business Officer
   Sale
   $229K 4,166 shares at $55.07 8.8% of stake
   Traded Oct 6 Filed Oct 6
   ↗
3. Paul V Maier Director
   Sale
   $3M 50,000 shares at $59.07 46% of stake
   Traded Aug 28 Filed Aug 31
   ↗
4. David Krempa Chief Business Officer
   Sale
   $1.6M 25,000 shares at $65.07 40% of stake
   Traded Aug 24 Filed Aug 24
   ↗
5. Sean Brynjelsen CEO
   Sale
   $6.1M 100,000 shares at $60.88 9.4% of stake
   Traded Aug 19–20 Filed Aug 20
   ↗
6. Opaleye Management Inc. 10% owner
   Sale
   $1.1M 28,315 shares at $37.54 41% of stake
   Traded Jul 14 Filed Jul 17
   ↗
7. Opaleye Management Inc. 10% owner
   Sale
   $4.8M 126,685 shares at $37.64 70% of stake
   Traded Jul 2–7 Filed Jul 7
   ↗
8. Jennifer McKie Adams Director
   Sale
   $1.6M 50,000 shares at $32.48 100% of stake
   Traded Jun 17 Filed Jun 17
   ↗
9. Sean Brynjelsen CEO
   Sale
   $3.8M 120,000 shares at $31.88 13% of stake
   Traded May 28 Filed May 29
   ↗
10. David Krempa Chief Business Officer
    Sale
    $3.2M 100,000 shares at $32.30 80% of stake
    Traded May 22–27 Filed May 27
    ↗

Also filed in the last 12 months, not counted as buying or selling: 16 option exercises and 7 share withholdings for taxes.